NYMOX REPORTS 2005 FINANCIAL RESULTS; PRODUCT SALES INCREASE BY 32%

Nymox Pharmaceutical Corporation announced today its financial results for the year ended December 31, 2005. Product sales increased by 32% and amounted to $424,506 for 2005, compared to $321,895 for 2004. Nymox currently has $11.9 million in financing available from its most recent October 21, 2005 financing. Nymox reported a net loss of $3,584,528, or $0.14 per share, compared to $3,745,625, or $0.15 per share for 2004. The weighted, diluted average number of common shares at December 31, 2005 was 26,103,704, compared to 25,103,252 at December 31, 2004.

CCN Matthews (http://www.ccnmatthews.com/news/releases/show.jsp?action=showRelease&searchText=false&showText=all&actionFor=584420)